Dr Reddy’s recalls six lots of drug in US owing to subpotency

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Dr Reddy’s Laboratories on Tuesday said it is voluntarily recalling from the US market six lots of medication, indicated to reduce blood phenylalanine (Phe) levels, on account of being subpotent.

The company is recalling affected lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level due to powder discolouration in some packets leading to decreased potency, the Hyderabad-based drug maker said in a regulatory filing.

The issue was discovered during an accelerated stability test in addition to customer complaints, it added. Reduced efficacy of the product would result in elevated Phe levels in patients.

Chronically elevated Phe levels in infants and children are likely to cause permanent neurocognitive deficits, including permanent and irreversible intellectual disability, developmental delay, and seizures.

Dr Reddy’s Laboratories Inc, the US-based arm of the company, has not received any reports of adverse events related to this recall to date, the company said.

Dr Reddy’s Laboratories Inc is notifying its distributors and customers by recall notification letters and arranging for returns of all recalled products, it said.

ALSO READ: Coca-Cola bets big on Microsoft’s AI with $1.1 billion deal

Anyone with an existing inventory of the product being recalled should examine the product and quarantine any of the recalled lots immediately, it added.

Consumers who have Sapropterin Dihydrochloride Powder for Oral Solution 100 mg from the affected lot should return it to their place of purchase, the company said.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow